PF-04518600 (anti-OX40 antibody)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-04518600 (anti-OX40 antibody), covering 2025-12-17 to 2025-12-17. Get the full timeline:
Most recent: Clinical Trial Update: Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer [Phase 2]